International Journal of Hematology

, Volume 91, Issue 2, pp 165–173

Molecular aspects of myeloproliferative neoplasms

Authors

  • François Delhommeau
    • Inserm, U1009, Institut Gustave RoussyUniversité Paris Sud
    • AP-HP, Laboratoire d’Hématologie, Hôpital Saint-AntoineUniversité Pierre et Marie Curie
  • Dorota Jeziorowska
    • AP-HP, Laboratoire d’Hématologie, Hôpital Saint-AntoineUniversité Pierre et Marie Curie
    • AP-HP, Laboratoire Commun de Biologie et Génétique Moléculaires, Hôpital Saint-AntoineUniversité Pierre et Marie Curie
  • Christophe Marzac
    • AP-HP, Laboratoire d’Hématologie, Hôpital Saint-AntoineUniversité Pierre et Marie Curie
    • Inserm, U1009, Institut Gustave RoussyUniversité Paris Sud
    • AP-HP, Laboratoire d’Hématologie, Hôpital Saint-AntoineUniversité Pierre et Marie Curie
Progress in Hematology Molecular mechanism, diagnosis, and treatment for myeloproliferative neoplasms

DOI: 10.1007/s12185-010-0530-z

Cite this article as:
Delhommeau, F., Jeziorowska, D., Marzac, C. et al. Int J Hematol (2010) 91: 165. doi:10.1007/s12185-010-0530-z

Abstract

During these past 5 years several studies have provided major genetic insights into the pathogenesis of the so-called classical myeloproliferative neoplasms (MPNs): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The discovery of the JAK2V617F mutation first, then of the JAK2 exon 12 and MPLW515 mutations, have modified the understanding of these diseases, their diagnosis, and management. Now it is established that almost 100% of PV patients present a JAK2 mutation. Nearly 60% of ET patients and 50% of patients with PMF have the JAK2V617F mutation. The MPLW515 mutations are also present in a small proportion of ET and PMF patients. These mutations are oncogenic events that cause these disorders; however, they do not explain the heterogeneity of the entities in which they occur. Genetic defects have not been yet identified in around 40% of ET and PMF. There are likely additional somatic genetic factors important for the MPN phenotype like the recently described TET2, ASXL1, and CBL mutations. Moreover, polymorphisms in the JAK2 gene have been recently described as associated with MPN. Additional studies of large cohorts are required to dissect the genetic events in MPNs and the mechanisms of these oncogenic cooperations.

Keywords

Myeloproliferative neoplasmsJAK2MPLTET2CBLASXL1

Copyright information

© The Japanese Society of Hematology 2010